In major news, BeiGene Ltd. has made significant developments in the bio-tech and oncology markets, starting with its successful Q1 2025 Earnings Call highlighting profitability and expansion. The company has also launched BeOne Medicines following redomiciliation to Switzerland, starting a new global oncology chapter and showcasing their ever-expanding hematological portfolio at EHA 2025. BeiGene, amidst these successes, has rebranded to BeOne Medicines and has secured royalty payments from Amgen for their lung cancer drug as we see collaboration with nference for B-cell Cancer Research. An extensive collaboration with InSysBio has expanded clinical trial modeling. Additionally, the U.S. Patent and Trademark Office has invalidated Pharmacyclics' patent asserted against BeiGene, leaving BeiGene to enjoy royalties from Amgen's lung cancer drug, Imdelltra. BeOne Medicines has been granted EU nod for Tevimbra and continues projecting a future of innovative cancer research. Finally, BeiGene's Q4 results promise positive earnings in 2025 and an eventual renaming as the company continues to solidify its aggressive global push.
BeiGene, Ltd. News Analytics from Wed, 09 Jun 2021 07:00:00 GMT to Sat, 21 Feb 2026 17:32:21 GMT -
Rating 7
- Innovation 6
- Information 8
- Rumor -4
